Arjuna’s turmeric extract granted ‘No Questions’ letter from the FDA

By Gary Scattergood

- Last updated on GMT

BCM-95 was granted self-affirmed GRAS status in 2016. ©iStock
BCM-95 was granted self-affirmed GRAS status in 2016. ©iStock
Arjuna Naturals Extracts’ BCM-95 turmeric extract has been granted a ‘No Questions’ response letter from the US Food and Drug Administration (FDA). 

The Indian firm says this confirms the safety of BCM-95 by the US authority and “helps position the ingredient as an all-natural, clean and trusted brand of the powerful curcumin antioxidant.”

BCM-95 is a proprietary combination of curcuminoids and essential oil of turmeric-ar-turmerone and has been the subject of 33 clinical studies.

In 2016, BCM-95 was granted self-affirmed GRAS status (Generally Recognized as Safe) by an expert panel of scientists for use in medical foods at a dose of 500 mg, twice a day.

“The FDA’s latest positive response is a testimony to our unwavering commitment to ensure maximum safety and quality products,”​ said Benny Antony, joint managing director for Arjuna.

The company recently completed construction of a new facility in Coimbatore, India, to produce the product.

The project was designed to triple the company’s curcumin capacity​ and maximise its efficiency and output, and at the same time reduce waste.

Related topics Suppliers

Follow us

Products

View more

Webinars